Abcam, ab300331, Human VEGF R1 (FLT1) ELISA Kit

Size: 96Tests
Human VEGF R1 (FLT1) ELISA Kit is a single-wash 90-min Simplestep used to quantify Human VEGF R1 (FLT1) with a sensitivity of 51.473 pg/ml. The assay uses a simple mix-wash-read protocol with just one incubation and one wash step. - Colorimetric Sandwich ELISA - 450 nm readout : works on any standard plate reader - Design your own immunoassay: we also offer the conjugation-ready antibody pair
Key facts
Detection method:Colorimetric,
Sample types:Tissue Extracts,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 51.473 pg/mL,
Range:156.25 - 10000 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)

Product details:
Human VEGF R1 (FLT1) SimpleStep ELISA® kit is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of VEGF R1 (FLT1) protein in human cell extract and tissue extracts. Quantitate Human VEGF R1 (FLT1) with 51.473 pg/ml sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
-Single-wash protocol reduces assay time to 90 minutes or less
-High sensitivity, specificity and reproducibility from superior antibodies
-Fully validated in biological samples
-96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (
ab203359
) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
VEGF Receptor 1 also known as FLT-1 is a protein that plays a critical role in the regulation of angiogenesis. Its mass is approximately 180 kDa. FLT-1 is a receptor tyrosine kinase expressed mainly on the surface of endothelial cells but also in monocytes and macrophages. The receptor binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) which initiates a series of signaling cascades important for vascular development and function.
Biological function summary
FLT-1 mediates important cellular responses such as cell migration and proliferation. Although it often functions in conjunction with other receptors like VEGFR-2 FLT-1 has unique binding affinities that modulate the availability of VEGF for other receptors. FLT-1 proteins as part of complex signaling networks actively contribute to maintaining vascular homeostasis and regulating blood vessel permeability.
Pathways
FLT-1 is an important component in the VEGF signaling pathway and also part of the PlGF/VEGF pathway. The receptor serves as a decoy to regulate the amount of VEGF interaction with VEGFR-2 influencing endothelial cell function and vascular permeability. By sequestering VEGF FLT-1 helps maintain the balance in this angiogenic signaling network interacting with proteins like VEGF PlGF and the anti-VEGF agents that target these pathways.
FLT-1 is implicated in cancer and diabetic retinopathy. Overexpression or dysregulation of FLT-1 can contribute to tumor angiogenesis which can enhance tumor growth and metastasis. In diabetic retinopathy abnormal FLT-1 activity affects retinal blood vessels leading to vision impairment. Similar interactions involve VEGFR-2 and other downstream effectors emphasizing the potential of FLT-1 as a therapeutic target for conditions associated with excessive angiogenesis and vascular dysfunction.